1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Short-Acting Bronchodilators 1.2.3 Corticosteroids 1.2.4 Methylxanthines 1.2.5 Long-Acting Bronchodilators 1.2.6 Phosphodiesterase-4 Inhibitors 1.2.7 Others 1.3 Market by Application 1.3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Clinic 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Perspective (2017-2028) 2.2 Chronic Obstructive Pulmonary Disorder (COPD) Growth Trends by Region 2.2.1 Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Region (2017-2022) 2.2.3 Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2023-2028) 2.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Dynamics 2.3.1 Chronic Obstructive Pulmonary Disorder (COPD) Industry Trends 2.3.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers 2.3.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges 2.3.4 Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue 3.1.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue (2017-2022) 3.1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Players (2017-2022) 3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder (COPD) Revenue 3.4 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio 3.4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2021 3.5 Chronic Obstructive Pulmonary Disorder (COPD) Key Players Head office and Area Served 3.6 Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service 3.7 Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Type 4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Type (2017-2022) 4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2023-2028) 5 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Application 5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Application (2017-2022) 5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028) 6.2 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) 6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028) 7.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) 7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028) 8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) 8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028) 9.2 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) 9.3 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2017-2028) 10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) 10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 GSK 11.1.1 GSK Company Detail 11.1.2 GSK Business Overview 11.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.1.5 GSK Recent Development 11.2 Pfizer 11.2.1 Pfizer Company Detail 11.2.2 Pfizer Business Overview 11.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.2.5 Pfizer Recent Development 11.3 Merck 11.3.1 Merck Company Detail 11.3.2 Merck Business Overview 11.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.3.5 Merck Recent Development 11.4 Novartis 11.4.1 Novartis Company Detail 11.4.2 Novartis Business Overview 11.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.4.5 Novartis Recent Development 11.5 AstraZeneca 11.5.1 AstraZeneca Company Detail 11.5.2 AstraZeneca Business Overview 11.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.5.5 AstraZeneca Recent Development 11.6 Boehringer Ingelheim 11.6.1 Boehringer Ingelheim Company Detail 11.6.2 Boehringer Ingelheim Business Overview 11.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.6.5 Boehringer Ingelheim Recent Development 11.7 Teva Pharmaceuticals 11.7.1 Teva Pharmaceuticals Company Detail 11.7.2 Teva Pharmaceuticals Business Overview 11.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.7.5 Teva Pharmaceuticals Recent Development 11.8 Ario Pharma 11.8.1 Ario Pharma Company Detail 11.8.2 Ario Pharma Business Overview 11.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.8.5 Ario Pharma Recent Development 11.9 Roche 11.9.1 Roche Company Detail 11.9.2 Roche Business Overview 11.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.9.5 Roche Recent Development 11.10 Ache 11.10.1 Ache Company Detail 11.10.2 Ache Business Overview 11.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.10.5 Ache Recent Development 11.11 Almirall 11.11.1 Almirall Company Detail 11.11.2 Almirall Business Overview 11.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.11.5 Almirall Recent Development 11.12 Aquinox Pharmaceuticals 11.12.1 Aquinox Pharmaceuticals Company Detail 11.12.2 Aquinox Pharmaceuticals Business Overview 11.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.12.5 Aquinox Pharmaceuticals Recent Development 11.13 Asmacure 11.13.1 Asmacure Company Detail 11.13.2 Asmacure Business Overview 11.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.13.5 Asmacure Recent Development 11.14 Astellas Pharma 11.14.1 Astellas Pharma Company Detail 11.14.2 Astellas Pharma Business Overview 11.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction 11.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) 11.14.5 Astellas Pharma Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Short-Acting Bronchodilators Table 3. Key Players of Corticosteroids Table 4. Key Players of Methylxanthines Table 5. Key Players of Long-Acting Bronchodilators Table 6. Key Players of Phosphodiesterase-4 Inhibitors Table 7. Key Players of Others Table 8. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 9. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2017-2022) & (US$ Million) Table 11. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2017-2022) Table 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2023-2028) Table 14. Chronic Obstructive Pulmonary Disorder (COPD) Market Trends Table 15. Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers Table 16. Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges Table 17. Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints Table 18. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Players (2017-2022) & (US$ Million) Table 19. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players (2017-2022) Table 20. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2021) Table 21. Ranking of Global Top Chronic Obstructive Pulmonary Disorder (COPD) Companies by Revenue (US$ Million) in 2021 Table 22. Global 5 Largest Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue (CR5 and HHI) & (2017-2022) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service Table 25. Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2017-2022) & (US$ Million) Table 28. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2017-2022) Table 29. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 30. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2023-2028) Table 31. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2017-2022) & (US$ Million) Table 32. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2017-2022) Table 33. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 34. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2023-2028) Table 35. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) & (US$ Million) Table 36. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) & (US$ Million) Table 37. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) & (US$ Million) Table 38. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) & (US$ Million) Table 39. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2017-2022) & (US$ Million) Table 40. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2023-2028) & (US$ Million) Table 41. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) & (US$ Million) Table 42. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) & (US$ Million) Table 43. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2017-2022) & (US$ Million) Table 44. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2023-2028) & (US$ Million) Table 45. GSK Company Detail Table 46. GSK Business Overview Table 47. GSK Chronic Obstructive Pulmonary Disorder (COPD) Product Table 48. GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 49. GSK Recent Development Table 50. Pfizer Company Detail Table 51. Pfizer Business Overview Table 52. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product Table 53. Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 54. Pfizer Recent Development Table 55. Merck Company Detail Table 56. Merck Business Overview Table 57. Merck Chronic Obstructive Pulmonary Disorder (COPD) Product Table 58. Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 59. Merck Recent Development Table 60. Novartis Company Detail Table 61. Novartis Business Overview Table 62. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product Table 63. Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 64. Novartis Recent Development Table 65. AstraZeneca Company Detail Table 66. AstraZeneca Business Overview Table 67. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product Table 68. AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 69. AstraZeneca Recent Development Table 70. Boehringer Ingelheim Company Detail Table 71. Boehringer Ingelheim Business Overview Table 72. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product Table 73. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 74. Boehringer Ingelheim Recent Development Table 75. Teva Pharmaceuticals Company Detail Table 76. Teva Pharmaceuticals Business Overview Table 77. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product Table 78. Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 79. Teva Pharmaceuticals Recent Development Table 80. Ario Pharma Company Detail Table 81. Ario Pharma Business Overview Table 82. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product Table 83. Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 84. Ario Pharma Recent Development Table 85. Roche Company Detail Table 86. Roche Business Overview Table 87. Roche Chronic Obstructive Pulmonary Disorder (COPD) Product Table 88. Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 89. Roche Recent Development Table 90. Ache Company Detail Table 91. Ache Business Overview Table 92. Ache Chronic Obstructive Pulmonary Disorder (COPD) Product Table 93. Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 94. Ache Recent Development Table 95. Almirall Company Detail Table 96. Almirall Business Overview Table 97. Almirall Chronic Obstructive Pulmonary Disorder (COPD)Product Table 98. Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 99. Almirall Recent Development Table 100. Aquinox Pharmaceuticals Company Detail Table 101. Aquinox Pharmaceuticals Business Overview Table 102. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD)Product Table 103. Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 104. Aquinox Pharmaceuticals Recent Development Table 105. Asmacure Company Detail Table 106. Asmacure Business Overview Table 107. Asmacure Chronic Obstructive Pulmonary Disorder (COPD)Product Table 108. Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 109. Asmacure Recent Development Table 110. Astellas Pharma Company Detail Table 111. Astellas Pharma Business Overview Table 112. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD)Product Table 113. Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) & (US$ Million) Table 114. Astellas Pharma Recent Development Table 115. Research Programs/Design for This Report Table 116. Key Data Information from Secondary Sources Table 117. Key Data Information from Primary Sources List of Figures Figure 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type: 2021 VS 2028 Figure 2. Short-Acting Bronchodilators Features Figure 3. Corticosteroids Features Figure 4. Methylxanthines Features Figure 5. Long-Acting Bronchodilators Features Figure 6. Phosphodiesterase-4 Inhibitors Features Figure 7. Others Features Figure 8. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application in 2021 & 2028 Figure 9. Hospital Case Studies Figure 10. Clinic Case Studies Figure 11. Chronic Obstructive Pulmonary Disorder (COPD) Report Years Considered Figure 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 14. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region: 2021 VS 2028 Figure 15. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players in 2021 Figure 16. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2021) Figure 17. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2021 Figure 18. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 19. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2017-2028) Figure 20. United States Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Canada Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2017-2028) Figure 24. Germany Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. France Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. U.K. Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Italy Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Russia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Nordic Countries Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2017-2028) Figure 32. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. South Korea Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. India Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Australia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2017-2028) Figure 40. Mexico Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Brazil Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2017-2028) Figure 44. Turkey Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2017-2028) & (US$ Million) Figure 46. GSK Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 47. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 48. Merck Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 49. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 50. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 51. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 52. Teva Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 53. Ario Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 54. Roche Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 55. Ache Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 56. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 57. Aquinox Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 58. Asmacure Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 59. Astellas Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2017-2022) Figure 60. Bottom-up and Top-down Approaches for This Report Figure 61. Data Triangulation Figure 62. Key Executives Interviewed

GSK Pfizer Merck Novartis AstraZeneca Boehringer Ingelheim Teva Pharmaceuticals Ario Pharma Roche Ache Almirall Aquinox Pharmaceuticals Asmacure Astellas Pharma